These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10967203)

  • 1. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat.
    Bojanowska E; Stempniak B
    Regul Pept; 2000 Jul; 91(1-3):75-81. PubMed ID: 10967203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.
    Larsen PJ; Tang-Christensen M; Jessop DS
    Endocrinology; 1997 Oct; 138(10):4445-55. PubMed ID: 9322962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucagon-like peptide-1 (7-36) amide on neurohypophysial hormone secretion induced by acute hyperosmotic challenge.
    Bojanowska E; Stempniak B
    Neuropeptides; 2003 Feb; 37(1):45-50. PubMed ID: 12637035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat.
    Bojanowska E; Stempniak B
    J Endocrinol; 2002 Feb; 172(2):303-10. PubMed ID: 11834448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36)amide on vasopressin and oxytocin release.
    Zueco JA; Esquifino AI; Chowen JA; Alvarez E; Castrillón PO; Blázquez E
    J Neurochem; 1999 Jan; 72(1):10-6. PubMed ID: 9886049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.
    Navarro M; Rodriquez de Fonseca F; Alvarez E; Chowen JA; Zueco JA; Gomez R; Eng J; Blázquez E
    J Neurochem; 1996 Nov; 67(5):1982-91. PubMed ID: 8863504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. tGLP-1 and release of vasopressin and oxytocin from the isolated rat hypothalamo-neurohypophysial system: effects of a tGLP-1 receptor agonist and antagonist.
    Bojanowska E; Stempniak B
    J Physiol Pharmacol; 2001 Dec; 52(4 Pt 2):781-93. PubMed ID: 11785773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin.
    Isbil-Buyukcoskun N; Gulec G
    Regul Pept; 2004 Apr; 118(1-2):33-8. PubMed ID: 14759554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms involved in glucagon-like peptide-1 (7-36) amide action on the rat hypothalamo-neurohypophysial system.
    Bojanowska E; Stempniak B
    Neuroendocrinology; 2003 Feb; 77(2):119-24. PubMed ID: 12624533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats.
    Rinaman L; Rothe EE
    Am J Physiol Regul Integr Comp Physiol; 2002 Jul; 283(1):R99-106. PubMed ID: 12069935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
    Barragán JM; Rodríguez RE; Eng J; Blázquez E
    Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.
    Dumoulin V; Dakka T; Plaisancie P; Chayvialle JA; Cuber JC
    Endocrinology; 1995 Nov; 136(11):5182-8. PubMed ID: 7588257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.
    Barragán JM; Rodríguez RE; Blázquez E
    Am J Physiol; 1994 Mar; 266(3 Pt 1):E459-66. PubMed ID: 8166268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.
    Barragán JM; Eng J; Rodríguez R; Blázquez E
    Am J Physiol; 1999 Nov; 277(5):E784-91. PubMed ID: 10567003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.
    Meeran K; O'Shea D; Edwards CM; Turton MD; Heath MM; Gunn I; Abusnana S; Rossi M; Small CJ; Goldstone AP; Taylor GM; Sunter D; Steere J; Choi SJ; Ghatei MA; Bloom SR
    Endocrinology; 1999 Jan; 140(1):244-50. PubMed ID: 9886831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon.
    Plaisancie P; Bernard C; Chayvialle JA; Cuber JC
    Endocrinology; 1994 Dec; 135(6):2398-403. PubMed ID: 7988423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs.
    Kawai K; Suzuki S; Ohashi S; Mukai H; Murayma Y; Yamashita K
    Acta Endocrinol (Copenh); 1990 Dec; 123(6):661-7. PubMed ID: 2284891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
    Ritzel R; Orskov C; Holst JJ; Nauck MA
    Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.